The Association Between COVID-19 Vaccination and Health-Related Quality of Life and Work Productivity: A Systematic Literature Review
Moderator
Jingyan Yang, DrPH, Pfizer Inc., New York, NY, United States
Speakers
Carolina Casañas i Comabella, Evidera, Oxford, United Kingdom; Tianyan Hu; Carlos Fernando Mendoza; Salima Punja; Heather Burnett; Hannah Volkman; Santiago Lopez; Rachel M Black, PharmD, AESARA, Austin, TX, United States; Manuela Di Fusco, MSc, Lancaster University, New York, NY, United States
OBJECTIVES: The value of vaccination from a health policy perspective expands beyond clinical efficacy/effectiveness and safety. This study characterized the association between COVID-19 vaccination and post-COVID health-related quality of life (HRQoL) and work productivity/impairment.
METHODS: A systematic literature review was conducted in Embase and MEDLINE to capture studies published between 1/1/2021-10/8/2024. Studies were included if they compared post-COVID HRQoL and/or work productivity/impairment in individuals of any age who received a COVID-19 vaccine (primary series or booster) versus another vaccine or no vaccine.
RESULTS: Five studies (9 publications) were included: n=2 reporting HRQoL and n=4 work productivity. Studies were conducted in adults in US (n=2), Greece (n=2), and Israel (n=1), and included healthcare workers (HCW) (n=2 studies), acute outpatient infections (n=2), patients hospitalized with COVID-19 (n=1), and patients with long-COVID (n=1). All studies assessed BNT162b2 (n=3 primary series only; n= 3 booster only; n=2 both primary series and booster). No other COVID-19 vaccines were studied. Two studies observed better EQ-5D utility index (UI) in individuals who received boosters (UI=0.83) versus unvaccinated (UI=0.76), driven by significantly lower symptom burden (p=0.002). Individuals with long-COVID who received a booster reported significantly higher EQ-5D UI versus unvaccinated (0.922 vs 0.731, p=0.014). Significantly lower presenteeism, work impairment, and productivity loss were reported in BNT162b2 versus unvaccinated. Long-COVID patients who had received a booster presented lower activity impairment versus unvaccinated. Vaccinated HCWs had significantly fewer absenteeism episodes versus unvaccinated (p<0.001) and significantly fewer days off work versus partially vaccinated (p<0.001).
CONCLUSIONS: Data on the association between COVID-19 vaccination and post-COVID HRQoL and work productivity are relatively scant and limited to BNT162b2. Studies consistently show that individuals vaccinated with BNT162b2 present better post-COVID HRQoL and work productivity than those unvaccinated or partially vaccinated based on local recommendations. Further research is needed for future adapted COVID-19 vaccines.
METHODS: A systematic literature review was conducted in Embase and MEDLINE to capture studies published between 1/1/2021-10/8/2024. Studies were included if they compared post-COVID HRQoL and/or work productivity/impairment in individuals of any age who received a COVID-19 vaccine (primary series or booster) versus another vaccine or no vaccine.
RESULTS: Five studies (9 publications) were included: n=2 reporting HRQoL and n=4 work productivity. Studies were conducted in adults in US (n=2), Greece (n=2), and Israel (n=1), and included healthcare workers (HCW) (n=2 studies), acute outpatient infections (n=2), patients hospitalized with COVID-19 (n=1), and patients with long-COVID (n=1). All studies assessed BNT162b2 (n=3 primary series only; n= 3 booster only; n=2 both primary series and booster). No other COVID-19 vaccines were studied. Two studies observed better EQ-5D utility index (UI) in individuals who received boosters (UI=0.83) versus unvaccinated (UI=0.76), driven by significantly lower symptom burden (p=0.002). Individuals with long-COVID who received a booster reported significantly higher EQ-5D UI versus unvaccinated (0.922 vs 0.731, p=0.014). Significantly lower presenteeism, work impairment, and productivity loss were reported in BNT162b2 versus unvaccinated. Long-COVID patients who had received a booster presented lower activity impairment versus unvaccinated. Vaccinated HCWs had significantly fewer absenteeism episodes versus unvaccinated (p<0.001) and significantly fewer days off work versus partially vaccinated (p<0.001).
CONCLUSIONS: Data on the association between COVID-19 vaccination and post-COVID HRQoL and work productivity are relatively scant and limited to BNT162b2. Studies consistently show that individuals vaccinated with BNT162b2 present better post-COVID HRQoL and work productivity than those unvaccinated or partially vaccinated based on local recommendations. Further research is needed for future adapted COVID-19 vaccines.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR46
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, STA: Vaccines